Terms: = Uterine cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
5 results:
1. MicroRNA-455-5p exerts inhibitory effect in cervical carcinoma through targeting S1PR1 and blocking mtor pathway.
Hu D; Sun S; Wang Y
Arch Gynecol Obstet; 2020 May; 301(5):1307-1315. PubMed ID: 32303890
[TBL] [Abstract] [Full Text] [Related]
2. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Boers-Sonderen MJ; de Geus-Oei LF; Desar IM; van der Graaf WT; Oyen WJ; Ottevanger PB; van Herpen CM
Target Oncol; 2014 Dec; 9(4):339-47. PubMed ID: 24577626
[TBL] [Abstract] [Full Text] [Related]
3. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases.
Schoolmeester JK; Howitt BE; Hirsch MS; Dal Cin P; Quade BJ; Nucci MR
Am J Surg Pathol; 2014 Feb; 38(2):176-88. PubMed ID: 24418852
[TBL] [Abstract] [Full Text] [Related]
4. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical Trials Group.
Oza AM; Elit L; Tsao MS; Kamel-Reid S; Biagi J; Provencher DM; Gotlieb WH; Hoskins PJ; Ghatage P; Tonkin KS; Mackay HJ; Mazurka J; Sederias J; Ivy P; Dancey JE; Eisenhauer EA
J Clin Oncol; 2011 Aug; 29(24):3278-85. PubMed ID: 21788564
[TBL] [Abstract] [Full Text] [Related]
5. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2011 Nov; 80(2):181-92. PubMed ID: 21134766
[TBL] [Abstract] [Full Text] [Related]
